Biotech Values

[poorgradstudent]

Interesting NEJM Question / Commentary that was brought to my attention by Biowatch.

Two independent groups cite observations in glioblastoma and NSCLC that patients responsive to Iressa tend to have cytoplasmic expression of EGF-R. It would be interesting if cytoplasmic expression becomes a validated biological finding in these tumours... it would have some consequences in the battle between small molecules and antibodies aimed at EGF-R.